Cantor Fitzgerald started coverage on shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) in a research report released on Tuesday, Marketbeat reports. The firm issued an overweight rating and a $22.00 target price on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Aldeyra Therapeutics’ FY2017 earnings at ($1.30) EPS and FY2018 earnings at ($1.29) EPS.

Other analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Aldeyra Therapeutics from a hold rating to a buy rating and set a $4.75 price objective for the company in a report on Thursday, August 10th. Canaccord Genuity reaffirmed a buy rating and set a $27.00 price objective (up from $12.00) on shares of Aldeyra Therapeutics in a report on Wednesday, September 13th. Cowen and Company reaffirmed an outperform rating and set a $14.00 price objective (up from $9.00) on shares of Aldeyra Therapeutics in a report on Thursday, September 14th. ValuEngine raised shares of Aldeyra Therapeutics from a strong sell rating to a sell rating in a report on Tuesday, September 12th. Finally, HC Wainwright set a $18.00 price objective on shares of Aldeyra Therapeutics and gave the stock a buy rating in a report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating and five have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $16.96.

Shares of Aldeyra Therapeutics (NASDAQ:ALDX) traded up 1.60% during trading on Tuesday, reaching $6.35. 163,819 shares of the company’s stock were exchanged. The company has a 50 day moving average of $7.01 and a 200 day moving average of $5.19. Aldeyra Therapeutics has a 52-week low of $3.80 and a 52-week high of $11.90. The firm’s market capitalization is $39.66 million.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.35) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. Equities analysts anticipate that Aldeyra Therapeutics will post ($1.47) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Cantor Fitzgerald Begins Coverage on Aldeyra Therapeutics, Inc. (ALDX)” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/10/28/cantor-fitzgerald-begins-coverage-on-aldeyra-therapeutics-inc-aldx.html.

In other news, major shareholder Life Sciences Maste Perceptive acquired 200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The stock was acquired at an average cost of $7.25 per share, with a total value of $1,450,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 28.40% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the business. Sphera Funds Management LTD. boosted its holdings in Aldeyra Therapeutics by 31.0% in the 2nd quarter. Sphera Funds Management LTD. now owns 875,931 shares of the biotechnology company’s stock valued at $4,117,000 after purchasing an additional 207,431 shares during the period. Virtu KCG Holdings LLC bought a new stake in Aldeyra Therapeutics in the 2nd quarter valued at $104,000. Vanguard Group Inc. boosted its holdings in Aldeyra Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after purchasing an additional 9,407 shares during the period. Hikari Power Ltd boosted its holdings in Aldeyra Therapeutics by 186.4% in the 2nd quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock valued at $507,000 after purchasing an additional 70,196 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in Aldeyra Therapeutics in the 1st quarter valued at $132,000. 40.32% of the stock is owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Analyst Recommendations for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.